Organon (OGN) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Organon (OGN) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 92.9% versus a loss of 1.3%. Over five years, VRDN leads with a +63.7% price change compared with -55.4% for OGN. Organon is the larger company by market cap ($3.65 billion vs $3.40 billion), about 1.1 times the size, while Viridian Therapeutics is growing revenue faster (+23359.9% vs -2.9%).
Organon pays a dividend yielding 0.58%, while Viridian Therapeutics does not currently pay one. Organon converts more of its revenue into profit, with a net margin of 3.0% versus -483.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OGN | VRDN |
|---|---|---|
| Share price | $13.89 | $29.96 |
| Market cap | $3.65B | $3.40B |
| 1-day change | -0.14% | -4.71% |
| YTD return | +93.72% | -3.73% |
| 1-year return | +92.92% | -1.25% |
| 5-year return | -55.38% | +63.72% |
| P/E ratio (TTM) | 17.81 | — |
| Forward P/E | 3.81 | — |
| EPS (TTM) | $0.78 | $-3.85 |
| Dividend yield | 0.58% | 0.00% |
| Annual dividend | $0.08 | $0.00 |
| Revenue (latest FY) | $6.22B | $70.85M |
| Revenue growth (YoY) | -2.92% | +23359.93% |
| Net income (latest FY) | $187.00M | $-342.60M |
| Gross margin | 53.30% | — |
| Operating margin | — | -512.91% |
| Net margin | 3.01% | -483.57% |
| 52-week high | $13.94 | $34.29 |
| 52-week low | $5.69 | $13.18 |
| Distance from 52-week high | -0.36% | -12.63% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -25.63% | +42.72% |
| Average volume | 2.74M | 2.14M |
| Shares outstanding | 262.62M | 113.56M |
| Employees | 10,000 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OGN has outperformed VRDN by 94.2 percentage points over the past year.
- Organon is more profitable, keeping 3.0 cents of every revenue dollar as net income versus -483.6 cents for Viridian Therapeutics.
- Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs -2.92%).
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
OGN vs VRDN FAQ
Which is bigger, Organon or Viridian Therapeutics?
Organon (OGN) is larger, with a market capitalization of $3.65B compared with $3.40B for Viridian Therapeutics (VRDN).
Which stock has performed better over the past year, OGN or VRDN?
OGN returned +92.92% over the past 12 months, compared with -1.25% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Organon or Viridian Therapeutics?
Organon pays a dividend yielding 0.58%, while Viridian Therapeutics does not currently pay a regular dividend.
Are Organon and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.